Read our Recent Headlines

November 25 Biotech Update

Trading is slow this week but news is not. Yesterday was better but I still think it is too early to call the sector back but at the very least.

November 23 Biotech Update

Of course, it is Thanksgiving week and the kids have off school so I will keep this focused on the big news of the day and that is the PFE/AGN.

November 20 Biotech Update

The sector still cannot gain real footing and follow positive days with additional positive days. That being said as long as the positive days either outnumber or have higher gains.

November 18 Biotech Update

It seems like every time I am out of town something major happens. I have not really followed the sector trading, so I cannot really comment on that but obviously.

November 13 Biotech Update

It has been a tough couple of days with pretty broad weakness but we will see how we end the week as many stocks have had a decent run so.

November 11 Biotech Update

The market seems mixed and searching for direction. It seems hard to see a clear trend in the sector or within the sector. Some large caps are strong and others.

LOXO: Staying On TRK

Loxo Oncology presented highly anticipated results from its ongoing Phase 1 study of TRK inhibitor LOXO-101 yesterday November 8, in a latebreaker at AACR-NCI-EORTC; they did not disappoint. Disclosure of.


Quick Facts














Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!